AVENTIS US PAT DEPT

RECEIVED CENTRAL FAX CENTER

NO. 9167

P. 21

OCT **1 9** 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

Kamal A Saeed

STROBEL et al.

Art Unit:

1626

Application No.: 10/073,160

Filed:

図

February 13, 2002

Pharmaceuticals

TELEFAX CERTIFICATE

Title: Acylated Indanyl Amines and Their Use as

I hereby certify that this correspondence is being transmitted via facsimile to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, at 571-273-8300, on

October 19, 2005

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

This Information Disclosure Statement is filed within the period set forth in §1.97(b) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, or before the mailing of a first office action after the filing of a request for continued examination under \$1.114 whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

	(p)	This Information Disclosure Statement is filed after the period set forth in 37 C.F.R.					
		1.97	7(b), but is believed to be filed before the mailing date of a final action under §1.113				
		or a	a notice of allowance under §1.311, whichever occurs first.				
		(1)	The undersigned attorney certifies that each item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application not more than three months prior				
			to the filing of this statement;				
		(2)	The undersigned attorney certifies that no item of information contained in this				
			Information Disclosure Statement was cited in a communication from a foreign				
			patent office in a counterpart foreign application or, to the knowledge of the				
			undersigned attorney after making reasonable inquiry, was known to any				
			individual designated in §1.56(c) more than three months prior to the filing of this				
			statement; or				
		(3)	This Information Disclosure Statement is accompanied by a transmittal letter in				
			which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is				
			authorized.				

Respectfully submitted,

Joseph Rossi, Reg. No. 47,038 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.
(a member of the sanofi-aventis group)
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, NJ 08807-0800
Telephone (908) 231-3410
Telefax (908) 231-2626
Aventis Docket No. DEAV2001/0004 US NP

DEAV2001/0004 - US - NP

1

Sheet

1

of

Please type a plue sign (+) inside this box -> Under the Pananwork Reduction Act of 1995, no persons are required to res	Petent and Traderr	PTO/SB/08A (10-96) proved for use through 10/31/99. OMB 0651-0031 nark Office: U.S. DEPARTMENT OF COMMERCE on unless it contains a valid OMB control number.	-
Substitute for form 1449A/PTO	Complete If Known		
	Application Number	10/073,160	Ì
INFORMATION DISCLOSURE	Filing Date	02-13-2002	ĺ
STATEMENT BY APPLICANT	First Named Inventor	STROBEL	
	Group Art Unit	1626	l
(use as many sheets as necessary)	Exeminer Name	SAFED Kemal A	•

Attorney Docket Number

•	U.S. PATENT DOCUMENTS							
xaminer nilials	Cite No.1	U.S. Patent Number	t Document Kind Codo ² (if Imawn)	Name of Patentee or Applicant	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines. Whore Rolevant Passages or Relevant Figures Appear		
		4,474,692		OKA, et al.	10-02-1984			
			•					
								
		·						
					 			
				·· ·· - · · ·				
		l			-			
-					 			
					†			
				Ų.				

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner initials	Cite No.1		Foreign Patent Docu	ment	Name of Patentee or	Date of Publication of	Peges, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T6
		Office	Number ⁴	Kind Code ³ (# Imown)	Applicant of Cited Document	Cited Document MM-DD-YYYY		
		JP	9071534 + Abstract		ISHIDA, et al.	03-18-1997		_
					<u> </u>	<u> </u>		1
							·	+
								T
					,			-
		}						十
\vdash								T

Examiner	Date	
Signature	Considered	
Ciginature	 	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will yary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinda of U.S. Patent Documents. ² Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the sertal number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard S7. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.